Page Title
Clinical Trial Finder
Anti-Inflammatory Closed to Enrollment
Phase 2 study of CTX-4430 in people with CF (EMPIRE) (Celtaxsys CTX-4430)
This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the anti-inflammatory drug CTX-4430 and will use a placebo control.
This study will look at the safety and effectiveness of the anti-inflammatory drug CTX-4430. Researchers will test CTX-4430 at two different doses. This study is placebo-controlled, meaning that some participants will receive the study drug, and others will receive a placebo. Researchers will test the effectiveness of CTX-4430 by measuring lung function. They will also test the drug’s safety by tracking adverse events.This trial is for people with CF who have had a pulmonary exacerbation in the last year. It may require blood draws, lung function tests and/or other measurements.
Eligibility
See other primary eligibility criteria for more information.
-
Age:
18 Years to 30 Years -
Mutation(s):
No Mutation Requirement -
FEV1% Predicted:
50% or greater
For more information about the results of this study and where it was conducted, visit ClinicalTrials.gov.
Other Primary Eligibility Criteria
Eligible patients will have had at least 1 acute pulmonary exacerbation in the 12 months prior to screening
Study Design
-
Study Type: ?more info
Interventional -
Randomized Study: ?more info
Yes -
Placebo Controlled: ?more info
Yes -
Length of Participation:
1 years -
Number of Study Visits:
15
Additional Information
-
Phase: ?more info
Phase Two -
Study Sponsor: ?more info
Celtaxsys -
Study Drugs:
Study Sites
-
Closed to Enrollment
Alabama
The Children's Hospital Alabama, University of Alabama at Birmingham, Birmingham, AL 35233
-
Closed to Enrollment
Alaska
Providence Alaska Medical Center, Anchorage, AK 99508
-
Closed to Enrollment
Arizona
Tucson Cystic Fibrosis Center, Tucson, AZ 85724
-
Closed to Enrollment
California
Children's Hospital of Los Angeles, Los Angeles, CA 90027
-
Closed to Enrollment
California
University of California at Davis Medical Center, Sacramento, CA 95817
-
Closed to Enrollment
California
Stanford University Medical Center, Palo Alto, CA 94304
-
Closed to Enrollment
Colorado
National Jewish Health, Denver, CO 80206
-
Closed to Enrollment
Connecticut
Yale University School of Medicine, New Haven, CT 06520
-
Closed to Enrollment
Florida
Central Florida Pulmonary Group, Orlando, FL 32803
-
Closed to Enrollment
Florida
University of Florida, Gainesville, FL 32610
-
Closed to Enrollment
Georgia
Children’s Healthcare of Atlanta and Emory University, Atlanta, GA 30322
-
Closed to Enrollment
Illinois
University of Chicago, Chicago, IL 60637
-
Closed to Enrollment
Illinois
OSF HealthCare Children’s Hospital of Illinois, Saint Francis Medical Center, Peoria, IL 61637
-
Closed to Enrollment
Kansas
University of Kansas Medical Center, Kansas City, KS 66160
-
Closed to Enrollment
Maine
Maine Medical Center, Portland, ME 04102
-
Closed to Enrollment
Massachusetts
Boston Children's Hospital, Boston, MA 02115
-
Closed to Enrollment
Massachusetts
Massachusetts General Hospital, Boston, MA 02114
-
Closed to Enrollment
Michigan
University of Michigan, Michigan Medicine, Ann Arbor, MI 48109
-
Closed to Enrollment
Michigan
Helen DeVos Children's Hospital, Grand Rapids, MI 49546
-
Closed to Enrollment
Michigan
Children's Hospital of Michigan, Detroit, MI 48201
-
Closed to Enrollment
Mississippi
University of Mississippi Medical Center, Jackson, MS 39216
-
Closed to Enrollment
New Mexico
University of New Mexico School of Medicine, Albuquerque, NM 87131
-
Closed to Enrollment
New York
Columbia University Cystic Fibrosis Program, New York, NY 10032
-
Closed to Enrollment
North Carolina
Wake Forest University Baptist Medical Center, Winston-Salem, NC 27157
-
Closed to Enrollment
Ohio
University of Cincinnati Medical Center, Cincinnati, OH 45267
-
Closed to Enrollment
Oklahoma
Oklahoma Cystic Fibrosis Center, OKC, OK 73104
-
Closed to Enrollment
Oregon
Oregon Health Sciences University, Portland, OR 97239
-
Closed to Enrollment
Pennsylvania
Children's Hospital of Philadelphia, Philadelphia, PA 19104
-
Closed to Enrollment
Pennsylvania
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA 15224
-
Closed to Enrollment
Pennsylvania
Hershey Medical Center Pennsylvania State University, Hershey, PA 17033
-
Closed to Enrollment
South Dakota
Sanford USD Medical Center, Sioux Falls, SD 57117
-
Closed to Enrollment
Tennessee
University of Tennessee Medical Center, Knoxville, TN 37920
-
Closed to Enrollment
Texas
Cook Children's Medical Center, Fort Worth, TX 76104
-
Closed to Enrollment
Texas
Dell Children's Medical Center of Central Texas, Austin, TX 78723
-
Closed to Enrollment
Virginia
Virginia Commonwealth University, Richmond, VA 23219
Eligibility
See other primary eligibility criteria for more information.
-
Age:
18 Years to 30 Years -
Mutation(s):
No Mutation Requirement -
FEV1% Predicted:
50% or greater
For more information about the results of this study and where it was conducted, visit ClinicalTrials.gov.
Other Primary Eligibility Criteria
Eligible patients will have had at least 1 acute pulmonary exacerbation in the 12 months prior to screening
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More